Breast Cancer Trial, Recruiting (NCT05293470)

Breast Cancer Trial, Recruiting NCT05293470 Sponsor: Novartis Pharmaceuticals Condition: Breast Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05293470 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Breast Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Women who have gone through menopause, or men, who have been diagnosed with a specific type of advanced or metastatic breast cancer that is hormone receptor-positive, HER2-negative, and has a PIK3CA gene mutation.
Patients whose cancer has gotten worse after previously receiving hormone-based treatment, and who are about to start a medication called Piqray for the first time, following the approved guidelines in Korea.
Patients who are willing to sign a written consent form agreeing to take part in the study.

Who may not be able to join:

Patients who cannot take Piqray due to a known serious allergic reaction to Piqray or any of its ingredients.
Women who are currently pregnant or breastfeeding.
Patients who are sexually active but are not willing to use contraception (birth control) while taking Piqray.
Patients who are receiving, or plan to receive, any other experimental or investigational medicine during the study period.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Phone: +41613241111

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05293470

Sponsor: Novartis Pharmaceuticals

Phase: Not Applicable

Status: Recruiting

Condition: Breast Cancer

Trial contact: +41613241111

More information: https://clinicaltrials.gov/study/NCT05293470

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Women who have gone through menopause, or men, who have been diagnosed with a specific type of advanced or metastatic breast cancer that is hormone receptor-positive, HER2-negative, and has a PIK3CA gene mutation.
Patients whose cancer has gotten worse after previously receiving hormone-based treatment, and who are about to start a medication called Piqray for the first time, following the approved guidelines in Korea.
Patients who are willing to sign a written consent form agreeing to take part in the study.

Who may not be able to join:

Patients who cannot take Piqray due to a known serious allergic reaction to Piqray or any of its ingredients.
Women who are currently pregnant or breastfeeding.
Patients who are sexually active but are not willing to use contraception (birth control) while taking Piqray.
Patients who are receiving, or plan to receive, any other experimental or investigational medicine during the study period.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Novartis Pharmaceuticals

Registry

ClinicalTrials.gov

Start date

29 June 2022

Est. completion

12 May 2027

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Incidence of AEs

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov